Telos Capital Management Inc. Buys 3,085 Shares of IQVIA Holdings Inc. $IQV

Telos Capital Management Inc. grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 7.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 44,091 shares of the medical research company’s stock after acquiring an additional 3,085 shares during the quarter. Telos Capital Management Inc.’s holdings in IQVIA were worth $8,375,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Physician Wealth Advisors Inc. increased its stake in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares in the last quarter. Westside Investment Management Inc. grew its holdings in shares of IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the last quarter. Atlantic Union Bankshares Corp bought a new stake in shares of IQVIA during the third quarter valued at approximately $36,000. Asset Dedication LLC raised its holdings in IQVIA by 224.0% in the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after acquiring an additional 168 shares during the last quarter. Finally, Trust Co. of Toledo NA OH bought a new position in IQVIA in the 2nd quarter valued at approximately $39,000. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Robert W. Baird set a $258.00 price target on IQVIA and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. JPMorgan Chase & Co. boosted their target price on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, January 25th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Finally, Stifel Nicolaus raised their target price on shares of IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $251.06.

IQVIA Trading Down 12.1%

Shares of IQV stock opened at $203.34 on Wednesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The company has a market cap of $34.63 billion, a price-to-earnings ratio of 27.89, a PEG ratio of 2.35 and a beta of 1.37. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The firm has a fifty day moving average price of $230.43 and a 200-day moving average price of $209.67.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.